MissionIR News - Cardium Therapeutics Excellagen® Recognized as Top 10 Innovation in Podiatry

Share Article

Company to introduce the wound care innovation at American Podiatric Medical Association (APMA) National Meeting in Washington, DC.

Excellagen activates human platelets, triggering the release of platelet-derived growth factors

MissionIR would like to highlight Cardium Therapeutics (NYSE MKT: CXM), a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.

In the company’s news yesterday,

Cardium Therapeutics reported that its professional-use Excellagen® (formulated collagen gel 2.6%) wound care product has been named one of the top ten podiatry innovations this year by the publication Podiatry Today. The company also told investors that it will be introducing the wound care product at the American Podiatric Medical Association (APMA) National Meeting (Booth 1910) being held August 16 – 19, 2012, in Washington, DC.

The report, titled “The Top 10 Innovations in Podiatry,” noted that “the product’s full-length collagen molecules are in their natural, fibrillar form, and are formulated in a unique physiologic buffer that ensures maintenance of the collagen molecule’s structure and function,” as stated by Arthur Tallis, DPM, a Fellow of the American Professional Wound Care Association and the American College of Foot and Ankle Surgeons, who was a clinical investigator in the multi-center Phase 2b MATRIX study. Those interested in reading the full article should visit http://www.podiatrytoday.com/top-10-innovations-podiatry?page=3. The article will also be published in the August 2012 print issue of Podiatry Today.

As reported by Podiatry Today, “Dr. Tallis has applied Excellagen following surgical debridement in the presence of blood cells and platelets,” and that “Excellagen activates human platelets, triggering the release of platelet-derived growth factors (PDGF).” With regard to the practice of podiatry and patient compliance, it was noted that “Excellagen can save time for the physician and patient as dressing changes are required only once a week.” In terms of ease of application and use, it was stated that “additional advantages of Excellagen are that no thawing or mixing of components is required prior to use,” and that “one can easily apply the formulation to wounds of all sizes and shapes, and the product achieves complete, even wound coverage without dripping.”

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

MissionIR Communications
Visit website